搜索
Abivax SA
ABVX添加自选
87.580USD
-2.620-2.90%
收盘 11-13 16:00（美东）
7.64B总市值
0.00市盈率 TTM
关于 Abivax SA 公司
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Abivax SA 简介
公司代码ABVX
公司名称Abivax SA
上市日期Jun 26, 2015
CEOde Garidel (Marc)
员工数量- -
证券类型Depository Receipt
年结日- -
公司地址7-11 Boulevard Haussmann
城市PARIS
上市交易所NASDAQ OMX - NASDAQ BASIC
国家France
邮编75009
电话33153830963
网址https://www.abivax.com/
公司代码ABVX
上市日期Jun 26, 2015
CEOde Garidel (Marc)
Abivax SA公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Kevin Shan, Ph.D.
Mr. Kevin Shan, Ph.D.
Vice President, Global Head - Biometrics
Vice President, Global Head - Biometrics
--
--
Dr. Dominik Hoechli, M.D.
Dr. Dominik Hoechli, M.D.
Independent Director
Independent Director
--
--
Ms. Nadege Briancon-Eris, Ph.D.
Ms. Nadege Briancon-Eris, Ph.D.
Senior Vice President, Global Head - Program Management
Senior Vice President, Global Head - Program Management
--
--
Ms. Mary Mantock
Ms. Mary Mantock
Senior Vice President, Global Head - Regulatory Affairs
Senior Vice President, Global Head - Regulatory Affairs
--
--
Ms. Hema Keshava
Ms. Hema Keshava
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Dr. Douglas Jacobstein, M.D.
Dr. Douglas Jacobstein, M.D.
Senior Vice President, Global Head - Clinical Development
Senior Vice President, Global Head - Clinical Development
--
--
Ms. Jennifer Fine
Ms. Jennifer Fine
Senior Vice President, Global Head - HEOR and RWE
Senior Vice President, Global Head - HEOR and RWE
--
--
Mr. Kim Kelly
Mr. Kim Kelly
Chief Technical Officer
Chief Technical Officer
--
--
Dr. Keith Fournier, Ph.D.
Dr. Keith Fournier, Ph.D.
Senior Vice President - Global Regulatory Affair
Senior Vice President - Global Regulatory Affair
--
--
Dr. Maurus de la Rosa, Ph.D.
Dr. Maurus de la Rosa, Ph.D.
Senior Vice President - Research
Senior Vice President - Research
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Kevin Shan, Ph.D.
Mr. Kevin Shan, Ph.D.
Vice President, Global Head - Biometrics
Vice President, Global Head - Biometrics
--
--
Dr. Dominik Hoechli, M.D.
Dr. Dominik Hoechli, M.D.
Independent Director
Independent Director
--
--
Ms. Nadege Briancon-Eris, Ph.D.
Ms. Nadege Briancon-Eris, Ph.D.
Senior Vice President, Global Head - Program Management
Senior Vice President, Global Head - Program Management
--
--
Ms. Mary Mantock
Ms. Mary Mantock
Senior Vice President, Global Head - Regulatory Affairs
Senior Vice President, Global Head - Regulatory Affairs
--
--
Ms. Hema Keshava
Ms. Hema Keshava
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Dr. Douglas Jacobstein, M.D.
Dr. Douglas Jacobstein, M.D.
Senior Vice President, Global Head - Clinical Development
Senior Vice President, Global Head - Clinical Development
--
--
常见问题
Abivax SA的前五大股东是谁？
Abivax SA 的前五大股东如下：Mr. Pierre Courteille
有多少机构持有Abivax SA(ABVX)的股份？
截至2026Q1，共有353家机构持有Abivax SA的股份，合计持有的股份价值约为61.40M，占公司总股份的78.18%。与2025Q4相比，机构持股有所增加，增幅为-289711.00。